Proposed Classes Ask To Combine Janssen Antitrust Suits
Four proposed classes suing Janssen Biotech for allegedly using sham patent litigation to keep a generic version of its prostate cancer drug off the market want a Virginia federal court to...To view the full article, register now.
Already a subscriber? Click here to view full article